Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157853 | 1.00 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL1543136 | 1.00 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL4157829 | 0.98 | CTSK (0.49) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL3947708 | 0.98 | CTSK (0.49) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL20273958 | 0.98 | CTSK (0.49) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL20438259 | 0.97 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL3545803 | 0.97 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL24065227 | 0.94 | CA1 (0.56) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL12794288 | 0.94 | CTSK (0.52) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL12794285 | 0.94 | CTSK (0.52) | CTSKBTKCA1CA2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3331877-B1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-09-22 | — | — | EP | disclosed |
| US-20210251992-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-08-19 | — | — | US | disclosed |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | BIOTHERYX, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-10376511-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-08-13 | — | — | US | disclosed |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ISRAELI COMPANY, OF (IL) | 2018-08-02 | — | — | US | disclosed |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ISRAELI COMPANY, OF (IL) | 2018-08-02 | — | — | US | disclosed |
| WO-2017021969-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-02-09 | — | — | WO | disclosed |
| EP-2597955-B1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| CN-1891689-A | Aliphatic nitrogen - containing 5 - membered ring compound | TANABE SEIYAKU CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-7138397-B2 | Nitrogenous 5-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| CN-1257891-C | Nitrogenous five-membered ring compound | TANABE SEIYAKU CO (JP) | 2006-05-31 | — | — | CN | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| CN-1468216-A | Nitrogenous five-membered ring compound | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | CTSK 4820/4885BTK 560/4885CA1 1297/4885 |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | CTSK 404/4885BTK 206/4885CA1 3312/4885 |
| US-20210251992-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | CTSK 404/4885BTK 206/4885CA1 3312/4885 |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | CTSK 3074/4885BTK 1775/4885CA1 4838/4885 |
| US-10376511-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | CTSK 404/4885BTK 206/4885CA1 3312/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | CTSK 4833/4885BTK 698/4885CA1 1274/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | CTSK 4828/4885BTK 637/4885CA1 1345/4885 |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | CTSK 404/4885BTK 206/4885CA1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.